We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 16 of 6476 for:    stem cells

Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02641769
Recruitment Status : Recruiting
First Posted : December 29, 2015
Last Update Posted : February 28, 2017
Information provided by (Responsible Party):
Stem Cells Arabia

Brief Summary:
This is an open label, single arm, single center investigation to assess the safety and efficacy of purified adult autologous bone marrow derived CD34+, CD133+, and mesenchymal stem cells injected into the seminiferous tubules and testis, through a 12 week follow-up period. The investigators' selected model of research is based on maximizing the efficiency of the approach by choosing an autologous pattern which preserves the genetic make-up of an individual that is vital in infertility conditions. Additionally the approach involves injecting a combination of different but purified cell types which all aid in the retrieval of spermatogenesis, and the generation of mature spermatozoa. Expected outcomes of this study are defined in general improvements in infertile patients in regards of testicular morphology, sexual function, semen quality, development of primary or secondary spermatocytes, spermatids, or mature spermatozoa in the testis, seminiferous tubules, or semen.

Condition or disease Intervention/treatment Phase
Non-obstructive Azoospermia Biological: Stem Cell Transplantation Phase 1 Phase 2

Detailed Description:

Non-obstructive azoospermia (NOA) is generally considered a non-medically manageable cause of male infertility. These patients, who constitute up to 10% of all infertile men, have abnormal spermatogenesis as the cause of their azoospermia. The etiology affecting approximately 60% of azoospermic men, includes non-obstructive causes of azoospermia, including toxic exposures or abnormal testicular development. NOA results from either primary testicular failure (elevated Luteinizing Hormone (LH), Follicle stimulating hormone (FSH), small testes affecting up to 10% of men presenting with infertility), secondary testicular failure (congenital hypogonadotropic hypogonadism with decreased LH and FSH, small testes), or incomplete or ambiguous testicular failure (either increased FSH and normal volume testes, normal FSH and small testes, or normal FSH and normal testis volume). Prior to microsurgical testicular sperm retrieval techniques and IVF/ICSI, donor insemination was the only option available to men with NOA. The establishment of in vitro fertilization using intracytoplasmic sperm injection (ICSI) as a standard treatment modality has resulted in a number of these men successfully fathering a child through surgically retrieved sperm from the testis. The challenge, however, is to improve their spermatogenic function to enable the appearance of sperm in their ejaculate or to improve the chances of a successful retrieval from the testis for ICSI.

The initial evaluation aims at resolving the following issues: (1) confirming azoospermia, (2) differentiating obstructive from non-obstructive etiology, (3) assessing for the presence of reversible factors and (4) evaluating for the presence of genetic abnormalities. An elevated follicle-stimulating hormone (FSH) level or an absence of normal spermatogenesis by testicular histology in the presence of azoospermia is generally considered sufficient evidence of a non-obstructive etiology. The most common reversible factors that need to be ruled out include recent exogenous hormone administration, severe febrile illnesses, chemotherapy/radiation or prolonged antibiotic use.

During past few years a considerable progress in the derivation of male germ cells from pluripotent stem cells has been made. These studies provide a desirable experimental model for elucidating underlying molecular mechanism of male germ cell development and potential strategies for producing haploid germ cells for the treatment of male infertility. Spermatogenesis is a complex process by which spermatogonial stem cells (SSC) self-renew and differentiate into haploid spermatozoa. In mammals, this process takes place in the seminiferous tubules of testis, which provide a functional niche for male germ cells and involve three major stages: mitosis, meiosis, and spermiogenesis. Errors at any stage of spermatogenesis can result in subfertility and infertility.

Researchers are currently developing alternative treatment options for these men involving stem cells. It has been verified that mouse induced pluripotent stem cells (iPSCs) can form functional spermatozoa. Functional assays have shown that spermatozoa generated from iPSCs were capable of fertilizing the oocytes after intracytoplasmatic injection and giving rise to fertile offspring following embryo transfer. So far, functional male gametes from human iPSCs have not been obtained.

There are two possible approaches in generating of male germ cells from pluripotent stem cells: in vitro differentiation into advanced, haploid cell products or combined in vitro differentiation and in vivo transplantation. However, the originality of this study is illustrated in the transplantation of purified autologous CD34+/CD133+ and mesenchymal bone marrow stem cells (BMSCs) into infertile patients without in vitro breeding, culture, or manipulation thus avoiding in vitro cell propagation risks as genetic mutations and DNA changes. The cells are withdrawn and injected back into the patient on the very same day of the procedure, hence conferring the highest safety and efficacy parameters.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intra-Testicular Transplantation of Purified Autologous Clusters of Differentiation (CD) 34+,133+, and Mesenchymal Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.
Study Start Date : January 2014
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : January 2019

Arm Intervention/treatment
Stem Cell Transplantation
intervention with transplantation of autologous purified stem cells
Biological: Stem Cell Transplantation
intervention with transplantation of autologous purified stem cells

Primary Outcome Measures :
  1. Appearance of different germ cells in testicles through the progress of spermatogenesis will be assessed by the count of cells using histological studies. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. General improvements of testicular morphology will be assessed with histological studies. [ Time Frame: 12 months ]
  2. Improvement in sexual function will be assessed using a questionnaire [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Infertile males with confirmed diagnosis of non-obstructive azoospermia (NOA)

Exclusion Criteria:

  • Patients with Obstructive Azoospermia (OA)
  • Previous surgical history in Testis
  • Patients with infectious genital diseases
  • Patients with anatomical abnormalities of the genital tract
  • Patients with major medical problems as malignancies
  • Chromosomal aberration (e.g. Y microdeletion, trisomy….)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02641769

Contact: Adeeb AlZoubi, PhD 00962795337575 adeebalzoubi@stemcellsarabia.net

Stem Cells of Arabia Recruiting
Amman, Jordan, 11953
Contact: Adeeb AlZoubi, PhD    00962795337575    adeebalzoubi@stemcellsarabia.net   
Sponsors and Collaborators
Stem Cells Arabia
Principal Investigator: Adeeb AlZoubi, PhD Stem Cells of Arabia

Responsible Party: Stem Cells Arabia
ClinicalTrials.gov Identifier: NCT02641769     History of Changes
Other Study ID Numbers: SCA-INF1
First Posted: December 29, 2015    Key Record Dates
Last Update Posted: February 28, 2017
Last Verified: December 2015
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Infertility, Male
Genital Diseases, Male
Genital Diseases, Female